Biotech Breakouts: 3 Stocks With Massive Upside Potential

Written by Chris Markoch

Investing in biotechnology stocks is complex due to the science behind the company’s drug candidates. They can be difficult to trade because these stocks are highly volatile, with double-digit moves in both directions a common occurrence.

However, biotech stocks offer a compelling risk-reward proposition as a long-term investment. The payoff in these three stocks can be massive for investors with the patience and time to hold them through the clinical trial phase.

Viking: An Obesity Challenger with Big Upside

Viking Therapeutics Inc. (NASDAQ: VKTX) surged higher in 2024 in sympathy with the popularity of GLP-1 weight loss drugs.

But in 2025, the stock has dropped more than 40%, including a 20% dip after its August clinical trial update. The results weren’t bad, with patients showing an average of 12.2% weight loss. Viking didn’t fail the trial in any sense.

Investors were concerned that those losses were shown at the highest dosage, which conflicts with competitors with similar or better results at lower doses. They were also reacting to a 28% dropout rate, which suggests the drug may have caused more side effects than preferred.

Does that justify a nearly 50% drop in VKTX stock? Analysts seem to think that reaction seems excessive and have issued a consensus price target of $87.50, indicating a bullish 270% upside from the stock’s current level.

The market for obesity drugs will be large enough to accommodate more than just the big two drug makers (i.e. Novo Nordisk and Eli Lilly). That makes this a good time for conviction investors to start accumulating.

Technically, VKTX appears to be bottoming. The relative strength indicator is around 34, approaching oversold territory, and the MACD shows signs that the bears are losing steam. After forming a death cross pattern in late August, investors should watch for signs of a golden cross as an indication of momentum.

ImmunityBio: A Penny Stock with Serious Potential

ImmunityBio Inc. (NASDAQ: IBRX) stock is up about 8.4% in 2025 with most of that gain coming in the last month. Why? In late August, the company revealed that all five patients in its pilot study with glioblastoma “attained 100% disease control” with a regimen that includes the company’s ANKTIVA drug.

ANKTIVA received FDA approval in April 2024 for bladder cancer treatment and is now in clinical trials for the treatment of other cancers. The company is also looking at the drug as a possible treatment for HIV and those with Long COVID.

This broad utility makes it one of the most exciting immunotherapy drugs in development.

Analysts have given ImmunityBio a consensus price target of $10.75, which would be a more than 280% gain. However, investors may want to wait for a slight pullback. However, caution is warranted in the short term. IBRX is trading above its 200-day SMA and has an RSI of 76, a historically resistant level for the stock.

Investors may want to wait for a pullback before initiating a position, but the long-term thesis remains intact. If ANKTIVA proves effective across multiple conditions, IBRX could move from penny stock status to biotech heavyweight.

Maze Therapeutics: Early Success in Rare Diseases

Maze Therapeutics Inc. (NASDAQ: MAZE) began publicly trading in February 2025. Since then, the stock is up approximately 86% and analysts believe there’s more room for growth.

On Sept. 11, Maze reported promising Phase 1 results for its lead candidate, MZE782, a potential treatment for phenylketonuria (PKU) and chronic kidney disease (CKD).

On Sept. 11, Maze announced positive results from its Phase 1 study of MZE782. This establishes proof of mechanism for a potent, oral SLC6A19 inhibitor with the potential to treat phenylketonuria (PKU) and chronic kidney disease (CKD). The key for investors is that the company can now take the trial into Phase 2.

That still leaves years to go before there’s FDA approval, and that’s no guarantee. However, analysts believe the stock has further to run. HC Wainwright is the most bullish with a $50 price target, which would mean MAZE stock would grow 2x from its current level.

Parabolic moves like the one in MAZE stock usually signal caution. The stock’s RSI is trending towards overbought, though the stock recently found support around the $22.40 level. Confirmation of that support would suggest that momentum is on the bulls’ side.

MAZE offers investors exposure to rare disease therapeutics—an area of biotech that often sees strong pricing power and lower competition. If clinical progress continues, the stock could see sustained gains.

READ THIS STORY ONLINE

Biden’s binge wiped out 20% of your buying power (Ad)

If the last few years taught investors anything, it’s that uncertainty hits fast. Inflation, policy shifts, and market shocks can erode buying power — and traditional retirement plans aren’t always built for turbulence.

Many savers are adding a measured allocation to hard assets like gold and silver to balance risk and preserve what they’ve worked for. A simple, step-by-step guide shows how everyday Americans are preparing — without “betting against” the broader economy.

REQUEST YOUR FREE GOLD & SILVER KIT TO SEE THE STEPS SMART INVESTORS ARE TAKING

Powering Up: A Buy Rating Signals GE Vernova’s AI Tailwinds

Written by Jeffrey Neal Johnson

A recent Buy upgrade from Melius Research has sharpened investor focus on GE Vernova (NYSE: GEV), accompanied by a new, optimistic $740 price target. This signal from Wall Street is underpinned by a powerful catalyst transforming the energy sector: the explosive growth of artificial intelligence (AI).

The immense electricity consumption required by AI data centers is creating a generational demand for new power generation and grid capacity. This places GE Vernova, a foundational builder of the world’s energy systems, in a prime position to capitalize on the build-out of the AI economy’s essential infrastructure.

A Structural Shift in Energy Needs

The engine of the AI revolution runs on electricity, and its appetite is voracious. The complex computations required to train and operate AI models demand massive, power-intensive data centers that consume energy on a scale previously unseen.

This surge in consumption is creating a structural shift in global energy demand, straining existing infrastructure and creating an urgent, multi-billion-dollar need to expand the energy backbone of the digital world.

Meeting this challenge requires a two-pronged solution. First, a significant increase in reliable power generation is necessary to produce the sheer volume of electricity needed.

Second, the electrical grid itself must be modernized and expanded to transmit these immense new loads from power plants to the data centers that need them. This dual requirement has created a powerful and sustained investment cycle for the companies that provide the essential equipment and services.

The Engine Room of the AI Revolution

GE Vernova’s power segment is directly addressing the need for more electricity generation, and its recent performance shows it. The segment reported a 44% organic increase in orders during the second quarter of 2025, a clear signal that utilities are moving quickly to add capacity.

These orders included 20 heavy-duty gas turbines and 27 aeroderivative units, the latter of which management explicitly linked to the AI boom.

For investors, this translates into strong revenue visibility. The company’s total backlog, a measure of future contracted revenue, grew to $128.7 billion. Its total gas equipment backlog and slot reservation agreements now stand at an impressive 55 gigawatts, providing a multi-year runway of future production.

Looking further ahead, GE Vernova’s progress on its BWRX-300 small modular nuclear reactor (SMR) positions it as a key long-term provider of the carbon-free, 24/7 baseload power that will be essential for the next generation of large-scale AI campuses.

The Grid’s Critical Upgrade Cycle

Generating more power is only half the solution; that energy must be reliably delivered. GE Vernova’s electrification segment provides the critical picks and shovels for this massive grid modernization effort. The segment’s performance underscores this powerful trend, posting an impressive 20% organic revenue growth in the second quarter of 2025.

The most direct evidence of the AI impact comes from the company’s CEO, who reported that GE Vernova secured nearly $500 million in data center-related orders in the first half of 2025 alone. This puts the company on pace to substantially surpass the $600 million in data center orders received for all of the prior year.

This demand has expanded the segment’s equipment backlog to approximately $24 billion, a more than $6 billion rise from the previous year. This growth is driven by the sales of essential hardware, including high-voltage transformers, switchgear, and advanced grid solutions.

These are the necessary components to connect new data centers to the power supply and ensure grid stability.

Translating Demand into Shareholder Value

The robust demand from the AI sector is translating directly into a stronger financial outlook for GE Vernova. Management’s confidence is clear, as it raised its full-year 2025 guidance for key metrics.

The adjusted EBITDA margin forecast increased from 8% to 9%, and the company raised its free cash flow projection by $1 billion to a new range of $3.0 to $3.5 billion.

This financial strength supports a robust capital allocation strategy, including a $6 billion share repurchase program. While the company’s wind segment continues to navigate its turnaround, its challenges are being decisively overshadowed by the immense strength and profitability of the power and electrification segments.

For investors, the Melius upgrade is a key indicator that the market is beginning to fully appreciate GE Vernova as a legacy industrial and a core enabling technology provider for the AI revolution. With a clear, data-supported growth runway, the recent analyst optimism appears well-founded.

READ THIS STORY ONLINE

3 BIG market opportunities ahead (Ad)

Quick question: Which trade do you wish you veered away from this month?

We’re kicking off with our game-changing Reversal Radar masterclass. This powerful system has consistently spotted major trend reversals across multiple assets, including a unique recent winner.

[SEE WHICH 3 STOCKS THE A.I. CHOSE →]

The Side of Rate Cuts Nobody Is Telling You About

Written by Gabriel Osorio-Mazilli

Macro is often an intimidating term for retail investors, as it encompasses everything from interest rates to inflation, employment, and global capital flows. However, macroeconomic forces are the true drivers behind every major market cycle.

Not Federal Reserve (the Fed) rate cuts or hikes, not earnings—its macro that determines whether industries soar or stumble.

Today, the macro picture is a bit confusing, as it is a mix of 2019 and 1974: softening economic data, rising inflation, and increasing unemployment. This current setup could easily turn into that scary word— stagflation—where high inflation with low economic growth squeezes consumers even further and creates a new super cycle.

This is why it’s important that investors look outside of equities, especially the tech sector, toward other asset classes like bonds, gold, and even Bitcoin, which could provide the diversity needed to weather the storm.

The Market Is Screaming Inflation—Are You Listening?

If you’re watching the charts, the message is loud: the U.S. dollar index is at a 52-week low, a clear sign that markets expect inflation to come roaring back. In fact, the latest CPI readings point to the United States trending close to 3% inflation again, far from the Fed’s preferred target of 2%.

At the same time, gold just keeps hitting new all-time highs, as is expected when the dollar weakens and inflation climbs. And then there’s Bitcoin, long debated as a digital inflation hedge, now behaving more and more like the real thing.

The bigger shock? The S&P 500 is also near record highs—an unusual divergence from traditional macro behavior. Normally, sustained inflation eats into corporate margins and valuations. So, how can markets rally in the face of these headwinds?

Now that the Fed has cut interest rates, chances are that a blow-off top rally across all asset classes will occur before the real consequences of inflation and weakening growth hit home.

Real Assets Are Primed for a Super Cycle

Cutting rates in an inflationary environment often triggers a super cycle in real assets like gold, silver, real estate, and industrial metals. We’re already seeing this play out as rare earth companies like  MP Materials Corp. (NYSE: MP) are on the move.

And Bitcoin is likely to follow as rate cuts devalue fiat currencies and push investors toward alternatives. One such company positioned to benefit is Bitcoin miner CleanSpark Inc. (NASDAQ: CLSK). With Wall Street analysts assigning a $20.50 price target, implying a potential 83% upside, CleanSpark could be a high-leverage way to ride this trend.

Bonds: The Silent Warning

Recent market momentum has favored gold and other metals, Bitcoin, and technology stocks, while most other sectors have lagged behind. Underpinning these moves, however, is the influence of the bond market, which continues to shape broader investor behavior.

Bonds typically move ahead of inflation expectations, since their prices are inversely related to yields, and yields often are attached to inflation expectations.

Today, the iShares 20+ Year Treasury Bond ETF (NASDAQ: TLT) is trading at only 90% of its 52-week high with a year-to-date (YTD) performance of just 3.5%. This means that the bond market isn’t convinced that rate cuts will lower yields. Instead, it sees something worse: inflation accelerating because of the cuts, not in spite of them. That’s a red flag for investors.

What Happens Next?

If the bond market is right, gold could easily surge past $4,000 per ounce. Bitcoin could smash through new all-time highs and deliver that CleanSpark upside. And equities, especially outside tech, could hit a wall because high inflation eventually suffocates growth and erodes valuations—even in a lower interest rate environment.

READ THIS STORY ONLINE

Unlock the A.I. Playbook: How to Avoid the Next Market Disaster (Ad)

Warren Buffett says “Be fearful when others are greedy.”

Our A.I. playbook shows you exactly when that moment arrives and how to position for maximum protection and profit potential.

This A.I. system just flagged five specific stocks showing pattern formations that suggest major trend reversals are imminent. These crystal-clear signals rarely align like this.

JOIN OUR LIVE A.I. STOCK WATCHLIST SESSION TO SEE ALL 5 STOCKS AND LEARN WHAT THE DATA REVEALS ABOUT